Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494258 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02494258 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 5 participants.
The verdict
NCT02494258, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Rollover study supporting hematological disorder indications from Celgene sponsored CC-486 (oral azacitidine) protocols eligible for participation in the study.
Interventions
- DRUG CC-486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-10-22 |
| Est. Completion | 2025-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02494258
The ClinicalTrials.gov registry entry for NCT02494258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-486 is the first listed.
NCT02494258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02494258 about?
NCT02494258 is a clinical study titled "A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders". Rollover study supporting hematological disorder indications from Celgene sponsored CC-486 (oral azacitidine) protocols eligible for participation in the study.
What is the current status of trial NCT02494258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2015-10-22. Estimated completion is 2025-04-14.
What interventions are being tested in trial NCT02494258?
The interventions under investigation include: CC-486 (DRUG).
Who is sponsoring clinical trial NCT02494258?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.